Our understanding of metastatic disease is constantly evolving. Although outcomes for patients with stage IV non-small cell lung cancer (NSCLC) are poor, aggressive/radical local intervention may be effective in a subset of patients with limited or "oligometastatic" disease. Here we review and compare the range of available treatment options that are specific to oligometastatic NSCLC, and discuss potential directions of future clinical research.